About the Immuno-Radiotherapy Working Group

☐ Several studies have demonstrated that radiation can modulate and enhance immune responses to tumors. Hypofractionation or other modifications of standard fractionation may promote immune responses to tumors, but other novel delivery options may also affect several immune responses including T-cell activation and changes in tumor-antigen presentation. However, there is limited understanding of the immunologic impact of hypo-and special multi-fractionated radiotherapy, as these observations are relatively recent. This NCI working group will bring together clinicians and researchers with an interest in radiotherapy and/or immunology to open a dialogue on the potential for exploiting radiation-induced immune responses in the context of cancer therapy.

Goals

☐ 1. To promote open dialogue on the potential for exploiting radiation-induced immune responses in the context of cancer therapy among radiotherapy and immunology clinicians and researchers.

WG Co-chairs

☐ Zachary Morris, M.D. (University of Wisconsin, zmorris@humonc.wisc.edu)
☐ Andrew Sikora, M.D. (Baylor College, andrew.sikora@bcm.edu)
☐ Samir Khleif, M.D. (Georgetown University, snk48@georgetown.edu)

The group membership is approximately 50.

Activities and Accomplishments

Clinical Trials:


2. Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer – CTEP Project Team Trial (https://clinicaltrials.gov/ct2/show/NCT02888743) (ClinicalTrials.gov Identifier: NCT02888743).

Publications


Workshops


Interested in becoming a member of the RI Working Group?

☐ Please Contact:

Masoor M. Ahmed, Ph.D.
Radiation Research Program
National Cancer Institute
Division of Cancer Treatment & Diagnosis
Tel: 240 276 5700
Email: mansoor.ahmed@nih.gov